Concepedia

Ai-Xi Yu

AY

Statistics

Publications

5

Citations

236

H-Index

5

Active since

2015

Affiliations

University of California, Davis(Current)

Wuhan University

Zhongnan Hospital of Wuhan University

Roswell Park Comprehensive Cancer Center

University of California Davis Medical Center

Ai-Xi Yu is an author at University of California, Davis specializing in oncology, noncoding rna in cancer, and osteosarcoma treatment.

Publications per year

2015–2021

5

Publications

5

Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics

Wanrong Yi, Mei‐Juan Tu, Zhenzhen Liu et al. · Acta Pharmaceutica Sinica B · 2019 · 67 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth

Yong Zhao, Mei‐Juan Tu, Yi-Feng Yu et al. · Biochemical Pharmacology · 2015 · 64 citations

Medicine, Oncology, Pharmacology +11

Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest

Yong Zhao, Mei‐Juan Tu, Wei-Peng Wang et al. · Scientific Reports · 2016 · 43 citations · Full text

Medicine, Oncology, Pharmacology +13

<i>In vivo</i> fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy

Peng-Cheng Li, Mei‐Juan Tu, Pui Yan Ho et al. · Theranostics · 2021 · 33 citations · Full text

Life Sciences, Biotechnology, Oncology +11

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models

Chao Jian, Mei‐Juan Tu, Pui Yan Ho et al. · Oncotarget · 2017 · 29 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 5